A commercial version of MarginScan, a device that detects cancerous cells using an impedance technology, will be developed by Milwaukee-based NovaScan for use in Mohs surgical treatment of skin cancer. The company, which will use the $2.5 million it recently raised in a $3.5 million financing round for product development, plans to initiate a pivotal trial next year and release the device in the US in 2019.
Milwaukee company to develop commercial version of cancer detection device
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.